TDAM USA’s GSK GSK Stock Holding History

TDAM USA’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-4,029	Closed	-$204K	–	329
2017 Q3	$204K	Hold	4,029	–	–	0.01%	322
2017 Q2	$218K	Hold	4,029	–	–	0.01%	314
2017 Q1	$212K	Sell	4,029 -360	-8%	-$18.3K	0.01%	323
2016 Q4	$211K	Sell	4,389 -144	-3%	-$7.11K	0.01%	330
2016 Q3	$244K	Buy	4,533 +544	+14%	+$29.8K	0.01%	331
2016 Q2	$216K	Sell	3,989 -80	-2%	-$4.21K	0.01%	333
2016 Q1	$206K	Sell	4,069 -1,304	-24%	-$64.9K	0.01%	341
2015 Q4	$271K	Sell	5,373 -1,744	-25%	-$88.9K	0.01%	323
2015 Q3	$342K	Hold	7,117	–	–	0.02%	313
2015 Q2	$371K	Sell	7,117 -1,586	-18%	-$89.3K	0.02%	318
2015 Q1	$502K	Sell	8,703 -348	-4%	-$20K	0.02%	318
2014 Q4	$484K	Sell	9,051 -8,616	-49%	-$482K	0.02%	242
2014 Q3	$1.01M	Buy	17,667 +3,033	+21%	+$186K	0.04%	177
2014 Q2	$978K	Buy	14,634 +556	+4%	+$37.6K	0.04%	186
2014 Q1	$940K	Buy	14,078 +380	+3%	+$25.7K	0.04%	189
2013 Q4	$914K	Buy	+13,698	New	+$888K	0.04%	186
2013 Q3	–	Sell	-20,434	Closed	-$1.32M	–	316
2013 Q2	$1.32M	Buy	+20,434	New	+$1.3M	0.06%	132

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TDAM USA's GSK Position: Q4 2017 in Review

TDAM USA sold out of GSK (GSK) in Q4 2017, closing a stake of 4,029 shares — an estimated $204K sold.

TDAM USA first reported a position in GSK in Q2 2013 and held it in 17 quarters. The position peaked at $1.32M in Q2 2013. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

TDAM USA reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
TDAM USA sold 4,029 GSK shares in Q4 2017, an estimated $204K.
TDAM USA first reported a position in GSK in Q2 2013 and held it in 17 quarters.
TDAM USA's GSK position peaked at $1.32M in Q2 2013.
763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on TDAM USA's 13F filing for Q4 2017, filed 2 Feb 2018.